Orano Med
Aaron Schatzmann is a skilled Scientist and Laboratory Specialist at Orano Med since May 2018. Prior experience includes serving as an Undergraduate Research Assistant and Biochemistry and Biophysics Lab Assistant at Texas A&M University from August 2016 to May 2018. Aaron Schatzmann holds a Bachelor’s Degree in Biomedical Sciences from Texas A&M University (2014-2018) and a Master’s Degree in Leadership from Dallas Baptist University (2018-2020).
Orano Med
1 followers
Based on an R&D program started in 2005, Orano Med has developed new processes for producing high-purity lead-212 (Pb-212), a rare radioactive isotope. Lead-212 is currently at the heart of promising projects in nuclear medicine to develop new treatments against cancer. The innovative approach, known as targeted alpha therapy (TAT), recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. Macrocyclics, Inc., an Orano Med company, is the global leader in high performance chelating agent technology, offering a broad range of services and products. For more information please visit www.macrocyclics.com.